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ABSTRACT
Background: Irritable bowel syndrome (IBS) is classified into 
subtypes according to bowel habit.
Objective: To investigate whether there are differences in 
clinical features, comorbidities, anxiety, depression and body mass 
index (BMI) among IBS subtypes. 
Methods: The study group included 113 consecutive patients 
(mean age: 48 ± 11 years; females: 94) with the diagnosis of IBS. 
All of them answered a structured questionnaire for demographic 
and clinical data and underwent upper endoscopy. Anxiety and 
depression were assessed by the Hospital Anxiety and Depression 
scale (HAD).
Results: The distribution of subtypes was: IBS-diarrhea (IBS-D), 
46%; IBS-constipation (IBS-C), 32%, and mixed IBS (IBS-M), 22%. 
IBS overlap with gastroesophageal reflux disease (GERD), functional 
dyspepsia, chronic headache and fibromyalgia occurred in 65.5%, 
48.7%, 40.7% and 22.1% of patients, respectively. Anxiety and/or 
depression were found in 81.5%. Comparisons among subgroups 
showed that bloating was significantly associated with IBS-M 
compared to IBS-D (odds ratio-OR-5.6). Straining was more likely 
to be reported by IBS-M (OR 15.3) and IBS-C (OR 12.0) compared 
to IBS-D patients, while urgency was associated with both IBS-M 
(OR 19.7) and IBS-D (OR 14.2) compared to IBS-C. In addition, 
IBS-M patients were more likely to present GERD than IBS-D (OR 
6.7) and higher scores for anxiety than IBS-C patients (OR 1.2). 
BMI values did not differ between IBS-D and IBS-C.
Conclusion: IBS-M is characterized by symptoms frequently 
reported by both IBS-C (straining) and IBS-D (urgency), higher levels 
of anxiety, and high prevalence of comorbidities. These features 
should be considered in the clinical management of this subgroup. 
Key words: Irritable bowel syndrome. Mixed-irritable bowel 
syndrome. Anxiety. Gastroesophageal reflux disease. Constipation. 
Diarrhea. Dunctional dyspepsia.
INTRODUCTION
Irritable bowel syndrome (IBS) is a common functional 
bowel disorder characterized by recurrent abdominal pain 
or discomfort associated with altered bowel habit (1). Sev-
eral studies have shown a considerable overlap of IBS with 
gastroesophageal reflux disease (GERD) and functional 
dyspepsia (FD) (2,3). In addition, nongastrointestinal 
somatic disorders and psychiatric disorders occur frequent-
ly in IBS (4,5). Comorbidity of IBS has been associated 
with increased use of health resources, impaired quality of 
life and poor outcome (6).
According to the Rome III criteria IBS is classified into 
subtypes by predominant stool pattern: IBS with diar-
rhea (IBS-D), IBS with constipation (IBS-C) and mixed 
IBS (IBS-M) (7). Pharmacologic treatment of IBS has 
been increasingly based on this categorization, but little 
is known about differences among subtypes regarding 
co-existent somatic and psychological disorders, which 
might influence the responses to treatment. The few studies 
which reported the distribution of IBS subtypes and com-
pared clinical and psychological characteristics between 
subgroups have shown contradictory results (8-11). 
Likewise, the nutritional consequences of chronic diar-
rhea in IBS-D patients still need clarification (12). Some 
studies found lower body mass index (BMI) in IBS-D 
in comparison with the other subtypes (13), while others 
showed increased BMI in this subgroup (14).
Therefore the aims of the present study were to assess 
the distribution of subtypes in a group of IBS patients 
referred to a tertiary center in Brazil, and to investigate 
whether there are differences among subtypes in clinical, 
psychological and nutritional features. 
METHODS
Patients
The study group included 113 consecutive patients (mean age: 48 
± 11 years; females: 94 patients) attending the outpatient gastroen-
terology clinic of our university hospital with the diagnosis of IBS. 
IBS was defined according to the Rome III criteria (7). Patients with 
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previous gastrointestinal tract surgery, diabetes mellitus, associated 
diseases that might cause intestinal dysmotility or in use of medi-
cations known to influence gastrointestinal transit were excluded 
from the study. 
Clinical evaluation
A standardized questionnaire was used to obtain information 
about demographic and clinical data, including the Rome III diag-
nostic questions for IBS. Symptoms of abdominal pain/discomfort, 
bloating, flatulence, borborygmus, straining, urgency, and bow-
el habits were assessed. In addition, characteristics of abdominal 
pain, such as frequency, location, relationship with food ingestion 
or defecation were recorded. Upper gastrointestinal symptoms and 
non-gastrointestinal symptoms, including headache, were also 
assessed. According to the Bristol stool form scale, IBS patients 
were divided into: IBS-C, IBS-D and IBS-M, as recommended by 
Rome III criteria (7). 
Upper digestive endoscopy
All patients underwent upper digestive endoscopy in order to 
identify lesions responsible for esophageal and dyspeptic symptoms. 
In addition duodenal biopsies were collected to exclude the presence 
of celiac disease. 
Comorbidity of IBS with GERD and FD
GERD was defined by weekly or more frequent typical heartburn 
or acid regurgitation, and was classified as non-erosive (NERD), in 
the absence of visible esophageal mucosal injury or erosive esoph-
agitis based on the endoscopic findings (15,16). FD was defined 
according to Rome III criteria by the presence of at least one of the 
following symptoms in the last 3 months: bothersome postprandial 
fullness, early satiation, epigastric pain or epigastric burning, with 
no significant pathological findings at upper endoscopy (17). 
Comorbidity with fibromyalgia 
The diagnosis of fibromyalgia was performed by a rheumatolo-
gist of our university hospital and was based on the American Col-
lege of Rheumatology criteria (18). 
Anxiety and depression
The presence of anxiety and depression was assessed by the Hos-
pital Anxiety and Depression (HAD) scale divided into subscales 
for anxiety and depression (19). The score for each subscale ranges 
from 0 to 21. Scores higher than 8 in either HAD subscales were 
considered to indicate anxiety or depression, respectively.
BMI
BMI was calculated for all patients. According to the World Health 
Organization classification, patients were classified into underweight 
(BMI < 18.50), overweight (BMI between 25 and 29.9 kg/m2), obese 
(BMI ≥ 30 kg/m2) and normal range (18.50-24.99 kg/m2).
Ethical approval
The study was approved by the institutional ethics committee. 
Each patient gave written informed consent before participation in 
the study.
Statistical analysis
Comparisons of the results were performed by the Chi-square 
test, Fisher’s exact test, one way ANOVA and the Kruskal-Wallis 
test. Logistic regression analysis was performed to determine the 
variables significantly associated with IBS subtypes. All statistical 
analyses were carried out using SAS System for Windows version 
9.4 (SAS Institute Inc., 2002-2012, Cary, NC, USA). A value of p < 
0.05 was considered to be statistically significant.
RESULTS
Clinical features
The demographic and baseline symptom profile of IBS 
patients and the distribution of clinical characteristics 
among subtypes are summarized in table I and figure 1. 
It can be seen that there was a preponderance of females 
(83%) in our series. The most frequent IBS subtype was 
IBS-D (46%), followed by IBS-C (32%) and IBS-M 
(22%). No significant differences were found among IBS 
Table I. Demographic features and BMI mean values in IBS patients. Comparisons among subtypes
Variables n (%) All 113 (100) IBS-D 52 (46) IBS-C 36 (32) IBS-M 25 (22) p
Gender
 Women
 Men
94 (83)
19 (17)
44 (84.6)
8 (15.4)
27 (75)
9 (25)
23 (92)
2 (8)
0.20
Age (years) 48 ± 11 47 ± 11 50 ± 13 48 ± 11 0.36
Symptoms duration (years) 9.1 ± 8.7 9.1 ± 8.1 7.5 ± 6.6 11.1 ± 12 0.60
BMI (kg/m2) 26.9 ± 5.4 26.4 ± 4.5 25.8 ± 5.6 29.4 ± 5 0.05
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subtypes in age, gender, symptoms duration and the fre-
quency of borborygmus, passage of mucus and flatulence. 
Table II shows the variables significantly associated 
with IBS subtypes after further analysis using logistic 
regression analysis. Bloating was reported by 76% of the 
study group, and was significantly associated with IBS-M 
in comparison with IBS-D (OD: 5.6; 95% confidence inter-
val [CI]: 1.2-26.5).
Defecation straining was reported by 32% of IBS 
patients, and it was significantly associated with both 
IBS-C (OD: 12.0; 95% CI: 3.6-40.3) and IBS-M (OD: 15.3; 
95% CI 4.2-55.5) in comparison with IBS-D. Urgency was 
associated with IBS-D (OD: 14.2; 95% CI: 1.8-113.2) and 
IBS-M (OD: 19.7; 95% CI: 2.3-168.8) compared to IBS-C. 
There were no significant differences among IBS sub-
types regarding the main characteristics of abdominal pain 
(Table III). Most patients complained of abdominal cramp-
ing at least once a day, which improved with defecation. Fig. 1. Abdominal symptoms reported by IBS-D, IBS-C and IBS-M patients.
Table II. Characteristics significantly associated with IBS subtypes according to logistic regression analysis
Variables Comparisons Odds ratio (95% CI) p
Straining IBS-C x IBS-D
IBS-M x IBS-D
12.0 (3.6-40.3)
15.3 (4.2-55.5)
< 0.0001
< 0.0001
Urgency IBS-D x IBS-C
IBS-M x IBS-C
14.2 (1.8-113.2)
19.7 (2.3-168.8)
0.01
0.006
Bloating IBS-M x IBS-D 5.6 (1.2-26.5) 0.03
Association with GERD IBS-M x IBS-D 6.7 (1.8-25.5) 0.004
Anxiety score IBS-M x IBS-C 1.2 (1.1-1.4) 0.02
BMI IBS-M x IBS-C
IBS-M x IBS-D
1.2 (1.1-1.3)
1.1 (1.1-1.3)
0.02
0.03
Table III. Characteristics of abdominal pain in IBS patients. Comparisons among subtypes
All n = 113 IBS-D n = 52 IBS-C n = 36 IBS-M n = 25 p
Abdominal cramping n (%) 98 (87.3) 46 (88) 26 (72) 24 (96) 0.02a
Location n (%)
– Diffuse
– Periumbilical
– Lower abdomen
47 (42)
37 (32.7)
23 (20.1)
22 (42)
18 (34.6)
10 (19.2)
12 (33)
11 (30.5)
11 (30.5)
13 (52)
8 (32)
2 (8)
0.34
0.92
0.09
Daily frequency n (%) 80 (71) 36 (75) 23 (72) 15 (65) 0.71
Improvement with defecation n (%) 75 (67) 36 (69) 21 (58) 19 (76) 0,32
Worsened by stress n (%) 58 (51) 27 (52) 18 (50) 13 (52) 0.98
Worse after meals n (%) 58 (51) 25 (48) 19 (52) 14 (56) 0.79
Time of the day n (%)
–  Anytime
– Post-meals
– Morning
– Nocturnal
70 (62)
23 (20.3)
14 (12.4)
6 (5.3)
33 (63.5)
13 (25)
4 (7.7)
2 (3.8)
23 (64)
5 (14)
6 (16.5)
2 (5.5)
14 (56)
5 (20)
4 (16)
2 (8)
0.78
0.44
0.37
0.74
ap > 0.05 by multivariate analysis.
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Abdominal pain was aggravated by stress or meal inges-
tion in 51% of patients. 
Celiac disease
The analysis of duodenal biopsies showed no case of 
celiac disease in our series.
Overlap with GERD or functional dyspepsia 
Table IV shows the comorbidity of IBS with other clin-
ical conditions. 
Overlap with GERD was observed in 74 IBS patients 
(65.5%). According to endoscopic evaluation GERD was 
non-erosive (NERD) in 80% of the cases. Logistic regression 
analysis showed that IBS-M patients were more likely to pres-
ent GERD than IBS-D patients (OD: 6.7; 95% CI: 1.8-25.5). 
Overlap between IBS and FD occurred in 55 patients 
(48.7%), with similar frequency in the three subtypes. 
Postprandial fullness was the most frequent symptom 
(78%) reported by FD patients. 
Headache and fibromyalgia
Chronic headache was reported by 41% of IBS patients, 
with no significant difference among subtypes. Fibromyal-
gia was diagnosed in 22% of the study group, with similar 
frequency in the three subtypes.
Anxiety and depression
Ninety patients completed the HAD scale. Table V 
shows the mean scores for anxiety and depression and the 
frequency of anxiety and/or depression for each subgroup. 
Overall, 83.3% of IBS patients had anxiety and/or depres-
sion according to the scale scores: 47 (52.2%) had anxiety 
associated with depression, 23 (25.5%) had anxiety and 
5 (5.5%) had depression. Comparing IBS patients with or 
without overlapping FD, there was no significant differ-
ence in the scores for anxiety (IBS + FD: 11.3 ± 4.9 vs. 
12.5 ± 4.5; p = 0.24) or depression (IBS + FD: 9.9 ± 5.4 
vs. 8.9 ± 4.1; p = 0.32). Similarly, there was no significant 
difference in HAD scores between IBS patients with or 
without GERD symptoms (p = 0.68).
The comparison among IBS subtypes showed that 
IBS-M patients were more likely to have higher scores for 
anxiety (OD: 1.2; 95% CI: 1.1-1.4) than IBS-C patients. 
BMI
According to BMI, 31% of IBS patients were classified 
as overweight and 29% as obese. Two patients were under-
weight, both belonging to the IBS-C subtype. BMI values 
were likely to be higher in IBS-M patients in comparison 
with IBS-C (OD: 1.2; 95% CI: 1.1-1.3) or IBS-D patients 
(OD: 1.1; 95% CI: 1.1-1.3). No significant difference was 
found between IBS-C and IBS-D patients regarding BMI 
values. 
DISCUSSION
In the present study the most frequent IBS subtype 
was IBS-D (46%), followed by IBS-C (32%) and IBS-M 
(22%). The distribution of IBS subtypes differs in different 
studies, and probably depends on the population evaluated, 
geographic location and the definition for each subtype 
(20). IBS-M was the largest bowel habit subgroup in recent 
Table IV. Comorbidity of IBS with other conditions. Comparisons among IBS subtypes
Comorbidities All n = 113 IBS-D n = 52 IBS-C n = 36 IBS-M n = 25 p
GERD n (%)
NERD in relation to GERD 
74 (65.5)
59 (79.7)
27 (52)
19 (70.3)
25 (69.4)
19 (76)
22 (88)
19 (86)
0.01
0.41
Functional dyspepsia 55 (48.7) 25 (48.1) 16 (44.4) 14 (56) 0.67
Headache 46 (40.7) 20 (38.4) 14 (39) 12 (48) 0.70
Fibromyalgia 25 (22.1) 10 (19) 6 (16.6) 9 (36) 0.16
Table V. Anxiety and depression in IBS patients according to HAD scores (n = 90). Comparisons among IBS subtypes
Variables All n = 90 SII-D n = 42 SII-C n = 28 SII-M n = 20 p
Score for anxiety 11.9 ± 4.8 11.9 ± 4.9 10.5 ± 5.2 13.8 ± 2.9 0.02
Score for depression 9.4 ± 4.8 9.4 ± 4.6 8.2 ± 5.3 11.1 ± 3.9 0.11
Anxiety and/or depression 75 (81.5%) 37 (88.1%) 18 (64.3%) 20 (100%) 0.006
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population-based studies performed in UK and the United 
States (10,21), while IBS-C was the most frequent among 
Iranian adults (11), and IBS-D the most frequent in tertiary 
hospitals in China (22). The increased prevalence of IBS-D 
in our study group may be explained by the fact that all 
patients were referred from primary care to our gastrointes-
tinal outpatient clinic. General practitioners may be more 
confident in the management of IBS-C, considering that 
IBS-D may demand a more complex investigation. Lin et 
al. (10) found an alternative diagnosis for 21% of patients 
referred from primary care as IBS-D, while no alternative 
diagnosis was made for IBS-C. The female predominance 
in our study group is in agreement with the data from the 
literature showing female:male ratios of 2:1 to 4:1 (23,24). 
It has been proposed that this preponderance of women 
may reflect differences in care-seeking behavior rather 
than the real incidence (24). 
All patients reported abdominal pain which was relieved 
by evacuation in most cases. Nocturnal pain was rare, in 
keeping with previous findings in functional gastrointesti-
nal diseases (25). With regard to pain location, our results 
could not confirm the observations of Bouchoucha et al. 
(26) showing characteristic sites of pain in IBS-C and 
IBS-M patients. Our finding that the majority (76%) of 
IBS patients complained of bloating corroborates that this 
is a supportive symptom for the diagnosis of IBS which 
should be taken into account in the therapeutic approach 
of these patients.
One limitation of the present study is that we did not 
assess the severity of pain in our patients. Heitkemper et 
al. (27) have shown that the severity of abdominal pain/
discomfort has a stronger effect on the quality of life than 
altered bowel pattern in IBS female patients. Based on 
these findings the authors suggested that the categoriza-
tion of IBS patients should include both abdominal pain/
discomfort severity and predominant bowel pattern. 
A large proportion of IBS patients were overweight or 
obese, which is consistent with recent data on the Bra-
zilian population (28). The comparison among subtypes 
showed no significant difference in BMI values between 
IBS-D and IBS-C, indicating that chronic diarrhea did 
not influence the nutritional status of IBS patients. These 
results are in agreement with those reported by Simrén et 
al. (29). However, it should be noted that BMI is only one 
parameter of the nutritional assessment, and further studies 
are necessary to investigate nutrient intake and specific 
nutritional deficits in these patients. On the other hand, 
our finding that about 50% of the study group related the 
exacerbation of their symptoms with meal ingestion is in 
agreement with the literature (12), and it reinforces the 
view that dietary intervention may have a role in the man-
agement of IBS.
The excessive comorbidity found in our IBS patients 
is consistent with the results of previous studies (4-6). 
The high prevalence of anxiety and depression confirms 
other reports (5,8,30) and emphasizes the importance of 
psychological assessment and treatment as part of clini-
cal management of IBS patients. The prevalence of both 
chronic headache and fibromyalgia was higher than that 
reported in population studies in Brazil (31,32) and simi-
lar to previous findings in IBS patients (5). Likewise, the 
frequency of overlapping with FD was similar to that pre-
viously reported (33). The 65.5% prevalence of GERD 
is within the range of 11-79% described in other studies 
(5,34). According to endoscopic evaluation the major-
ity of the cases were classified as NERD, as expected 
(35). However the present study was unable to confirm 
the association between comorbidity and psychological 
distress in IBS, as reported by several authors (5,36). 
We believe that this may be due to a lack of statistical 
power to identify differences, given the small number 
of patients without anxiety or depression in our study 
population. 
The comparisons among IBS subtypes identified some 
special characteristics of IBS-M subtype. Patients of this 
subgroup complained of symptoms commonly seen in 
IBS-C (straining) and IBS-D (urgency), as shown in other 
studies (21,37). This should be taken into account during 
treatment with medications with significant effects on 
colonic motility or stool consistency, which could improve 
some symptoms, with no relief or even aggravation of oth-
ers. In addition, IBS-M patients were likely to present high-
er scores for anxiety, especially in comparison with IBS-C. 
This is a relevant finding, considering that psychological 
factors have been previously shown to contribute to poor 
outcomes, influencing symptoms severity and response to 
therapy (38). A few studies have compared psychologi-
cal disturbances among IBS subtypes. Tillisch et al. (39) 
reported increased psychological comorbidity in IBS-M. 
Muscatello et al. (9) showed that IBS-C patients were more 
psychologically distressed than IBS-D. In contrast, Rey de 
Castro et al. (8) found no difference in anxiety/depression 
levels among the three subgroups. 
Moreover the frequency of GERD was higher in IBS-M 
patients, particularly when compared to IBS-D. One expla-
nation for this association could be the higher BMI values 
found in IBS-M patients of our study group, since high 
BMI has been shown to be a predictor of IBS-GERD over-
lap (40). An alternative explanation could be the increased 
levels of anxiety seen in our IBS-M patients, considering 
that comorbid disorders have been previously related to 
anxiety and depression in IBS (5). 
Taken together, these features indicate that treatment of 
IBS-M patients may be challenging, as recently suggested 
by Tillish et al. (39) and Su et al. (41). 
In conclusion, IBS-D was the most frequent subtype in 
IBS patients referred to a tertiary center in Brazil. IBS-M 
is characterized by symptoms frequently reported by both 
IBS-C (straining) and IBS-D (urgency), higher levels of 
anxiety and high prevalence of comorbidities. These par-
ticular features require special attention in the therapeutic 
management of IBS-M patients. 
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